NDC product
SPORANOX
NDC 50458-290 · Janssen Pharmaceuticals, Inc.
Key facts
| Product NDC | 50458-290 |
|---|---|
| Proprietary name | SPORANOX |
| Nonproprietary name | ITRACONAZOLE |
| Substances | ITRACONAZOLE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | Janssen Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA020083 |
| Pharmacologic classes | Azole Antifungal [EPC], Azoles [CS], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Sep 11, 1992 |
| Marketing end | Nov 30, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory